Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Stock Up 5.1%

PVLA stock traded up $5.74 on Monday, reaching $118.84. 231,409 shares of the company’s stock were exchanged, compared to its average volume of 279,634. The stock has a fifty day moving average of $118.63 and a 200-day moving average of $109.05. The firm has a market cap of $1.70 billion, a PE ratio of -28.50 and a beta of -0.14. Palvella Therapeutics, Inc. has a twelve month low of $20.35 and a twelve month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities research analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. HC Wainwright increased their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Truist Financial set a $210.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $199.53.

Institutional Trading of Palvella Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of PVLA. Avidity Partners Management LP grew its position in shares of Palvella Therapeutics by 262.7% in the first quarter. Avidity Partners Management LP now owns 70,000 shares of the company’s stock valued at $8,726,000 after purchasing an additional 50,700 shares during the last quarter. Arete Wealth Advisors LLC acquired a new position in shares of Palvella Therapeutics during the 1st quarter worth approximately $2,178,000. Bank of America Corp DE raised its position in shares of Palvella Therapeutics by 25.4% during the 1st quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock worth $4,733,000 after purchasing an additional 7,700 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Palvella Therapeutics by 688.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock valued at $2,232,000 after buying an additional 15,637 shares in the last quarter. Finally, First Light Asset Management LLC grew its holdings in Palvella Therapeutics by 38.3% during the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares during the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.